Oral contraceptives and hepatocellular carcinoma

Oral contraceptives and hepatocellular carcinoma.

A series of 26 white women aged under 50 who developed hepatocellular carcinoma in a non-cirrhotic liver were studied for the possible role of oral contraceptives. Eighteen of the women had used the "pill" for a median of eight years. Over 1300 women whose use of the pill had been determined in another study served as controls. Patients and controls were divided into five age and four calendar ...

Hepatocellular Carcinoma in Sheep

Oral contraceptives and cervical carcinoma in situ in Chile.

A case-control study of cervical carcinoma in situ was conducted in Santiago, Chile, to determine whether risk of this condition is altered by use of oral contraceptives. Responses to a standardized questionnaire were compared in 133 hospitalized cases and 254 age-matched controls selected from the same screening program through which the cases were detected. After controlling for the possible ...

Oral Contraceptives

Current low dose OCs are highly effective with an excellent safety profile and many associated health benefits No single product has been shown to be superior in efficacy, safety or tolerability There is no "one size fits all" OC; different women may require different formulations Smoking particularly after age 35 with concurrent OC use greatly increases cardiovascular and thrombotic risks Age ...

Oral contraceptives and exercise.

A laboratory study was undertaken with volunteer females (aged 20-25) to determine the effect of OCs (oral contraceptives) on hematologic and metabolic variables during exercise. 5 of the women studied were naturally cycling and 7 were taking OCs. The women worked at 2 workloads on a bicycle ergometer at 50% and 90% of their maximal aerobic capacity during 3 different phases of their menstrua...